Patients who are currently receiving drugs that are moderate to strong inducers or inhibitors of CYPA are not eligible; moderate to strong inducers or inhibitors of CYPA should be avoided from  days prior to enrollment to the end of the study; Note: CYPA inducing anti-epileptic drugs and dexamethasone for CNS tumors or metastases, on a stable dose, are allowed
Strong inhibitors and strong or moderate inducers of CYPA
ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Patients should not have received the following within  days prior to the first dose of study drug:\r\n* Steroid therapy for anti-neoplastic intent;\r\n* Strong and moderate CYPA inhibitors;\r\n* Strong and moderate CYPA inducers
ELIGIBILITY CRITERIA - PHASE II (ARM D): Patients should not have received the following within  days prior to the first dose of study drug:\r\n* Steroid therapy for anti-neoplastic intent;\r\n* Strong and moderate CYPA inhibitors;\r\n* Strong and moderate CYPA inducers
Patients treated within the last  days prior to the start of IP with strong/moderate CYPA inhibitors, strong/moderate CYPA inducers, CYPC inhibitors, strong/moderate CYPC inducers, or drugs that are known to prolong the QT interval.
Participants that require co-administration of strong or moderate CYPA inhibitors, as these medications may alter dabrafenib and trametinib concentrations
Participants who require treatment with medications that are strong or moderate CYPA inducers, as these medications may alter the concentration of trametinib
Require continued treatment with a medication that is known to be a strong inhibitor of CYPA enzymes. (Treatment with moderate or weak CYP enzyme inhibitors is allowed.)
Treatment with strong to moderate CYPA inhibitors or moderate CYPA inducers within  days prior to the first dose of study treatment.
Prior treatment (<  weeks before start of SY-) with moderate or strong CYPA inducers or strong CYPA inhibitors. See list in Appendix 
Participants that require co-administration of strong or moderate CYPA inhibitors, as these medications may alter vemurafenib and cobimetinib concentrations
Participants who require treatment with medications that are strong or moderate CYPA inducers, as these medications may alter the concentration of cobimetinib
Taking any medication known to be a moderate or strong inhibitor of the CYPA isozyme or any drugs that are moderate or strong CYPA inducers.
Concurrent treatment with a non-permitted drug as well as foods or supplements that are strong or moderate CYPA enzyme inducers or inhibitors. Any of the above has to be discontinued at least  days prior to cycle / day  of study treatment.
Subject has received the following within  days prior to the first dose of the study drug:\r\n* Steroid therapy for anti-neoplastic intent\r\n* Strong and Moderate CYPA inhibitors \r\n* Strong and Moderate CYPA inducers
Consumption of foods, supplements, or drugs that are strong or moderate CYPA enzyme inducers or inhibitors at least  days prior to Day  of Cycle  and during study treatment
Participant has received strong and/or moderate CYPA inducers within  days prior to the initiation of study treatment; additional details as described in the protocol.
Patients receiving any medications or substances that are strong inhibitors and/or strong or moderate inducers of CYPA are ineligible
Participant has received strong or moderate CYPA inducers  days prior to the initiation of study treatment.
Chinese participants are excluded from receiving strong and/or moderate CYPA inhibitors  days prior to the initiation of study treatment through the end of intensive PK collection ( hours post dose on Cycle  Day ).
Receiving, or received, concomitant medications, herbal supplements and/or foods that significantly modulate CYPA inhibitors or moderate CYPA inhibitors, strong CYPA inducers or moderate CYPA inducers
Participants must not be on medications, including antiretroviral (ARV) regimens such as cobicistat, indinavir, or ritonavir, or agents with moderate or strong CYPA inhibition; if on a moderate or strong CYPA inhibitor regimen prior to study enrollment, participants must be switched to a qualifying regimen with the last dose of the strong CYPA inhibitor taken at least one week before administration of ibrutinib
Concomitant use of known strong cytochrome P (CYP) A (CYPA) inhibitors or moderate CYPA inhibitors. Concomitant use of known strong or moderate CYPA inducers.
Concurrent administration of strong inhibitors or moderate inducers of CYPA is not permitted; administration must be discontinued at least  days prior to initiating study drug administration.
Use of moderate to strong CYPA inhibitors within  weeks prior to start of study treatment
Strong or moderate CYPA inhibitors within  days prior to day  of protocol therapy
Strong or moderate CYPA inducers within  days prior to day  of protocol therapy
Received strong cytochrome (CYP) A inhibitors, moderate CYPA inhibitors, strong CYPA inducers and moderate CYPA inducers within  days prior to initiation of study treatment
Concomitant use of strong and moderate CYPA inhibitors and inducers
Patients must not be taking, nor plan to take while on protocol treatment and for  days after the last dose of study treatment, drugs, herbal supplements or foods that are known to be strong/moderate CYPA or CYPD inhibitors and/or inducers
For Cohort A: Is currently receiving strong or moderate inducers of CYPA
Use of moderate/strong cytochrome P (CYP)A inhibitors or moderate/strong CYPA inducers within  weeks prior to the first dose of study drug (with the exception of enzalutamide in the combination arms)
Use of moderate/strong cytochrome P (CYP)A inhibitors or moderate/strong CYPA inducers within  weeks prior to the first dose of study drug
Patients requiring treatment with moderate CYPA inhibitors
Moderate to strong CYPA inducers
Concomitant use of known strong or moderate CYPA inhibitors
Concomitant use of known strong or moderate CYPA inducers
Participants requiring any medications or substances that are strong inducers or inhibitors of CYPA are ineligible; those who may discontinue these medications are eligible after a  day washout period; mild or moderate inducers or inhibitors of CYPA are permitted but moderate inhibitors will require dose reduction of ibrutinib
Received agents known to be strong and moderate Cytochrome P A inhibitors or inducers within  days prior to the first dose of study drug
For ARMS A, C and D, unable or unwilling to discontinue use of any drug known to be a strong or moderate inhibitor or inducer of CYPA (prohibited inducers must be discontinued within  weeks prior to first dose of study drug); please note that cotreatment with weak inhibitors of CYPA is allowed
Concomitant use of known strong CYPA inhibitors or moderate CYPA inhibitors;
Concomitant use of known strong or moderate CYPA inducers;
Strong or moderate CYPA inhibitors or inducers
Subject requires either moderate or strong (if weak,  or more) inhibitors or inducers of Cytochrome P A (CYPA) mediated metabolism.
Use of strong/moderate CYPA inhibitors.
Use of moderate or strong cytochrome P (CYP) A inhibitors or CYPA inducers within  weeks before the first dose of study drug.
Systemic treatment with moderate and strong cytochrome P (CYP) CYPA inhibitors or inducers must be discontinued at least  days before the first dose of MLN. Moderate and strong CYPA inhibitors and CYPA inducers are not permitted during the study. Participants must have no history of amiodarone use in the  months before the first dose of MLN.
Systemic treatment with strong and moderate inhibitors of CYPA, strong and moderate inhibitors of CYPA, or clinically significant CYPA inducers or use of Ginkgo biloba or St. John's wort within  days before the first dose of study drug
Strong and moderate Cytochrome P A (CYPA) inhibitors (Part  Dose Determination);
Strong and moderate CYPA inducers (Part  Dose Determination and Part  Cohort Expansion).
Received a strong or listed moderate inhibitor of CYPA < weeks prior to first study dose
Use of strong and moderate CYPA inhibitors and inducers =<  days prior to registration
Subject who has received strong/moderate inhibitors or inducers of CYPA within  days prior to the first dose of study drug.
No concurrent use of moderate/strong CYPA inhibitors, or strong CYPA inducers
Medications or supplements that are known to be moderate mechanism-based inhibitors or moderate inducers of CYPA within  days or within  times the inhibitor or inducer half-life (whichever is longer) before the first dose of study drugs. In general, the use of these agents is not permitted during the study for this combination except in cases in which an AE must be managed. See a list of nonexhaustive moderate CYPA mechanism-based inhibitors or moderate CYPA inducers based on the US FDA Draft DDI Guidance.
Prohibited medications: patients taking CYPA enzyme inducers and moderate or strong inhibitors will be excluded from this trial
Concurrent administration of medications or foods that are moderate or strong inhibitors or inducers of CYPA within  days prior to first dose of study drug
Use of any drugs or substances known to be strong or moderate inhibitors of CYPA and CYPD enzymes within  week prior to Day  or planned to be used during the overall study period.
Systemic treatment with moderate or strong CYPA inhibitors or inducers must be discontinued at least  days before the first dose of alisertib, and the use of these agents is not permitted during the study (except for the protocol-specified administration of itraconazole).